Glucagon Dosage for Hypotension
For hypotension refractory to standard measures in the setting of β-blocker toxicity, administer an initial intravenous glucagon bolus of 3-10 mg over 3-5 minutes, followed by a continuous infusion of 3-5 mg/hour (0.05-0.10 mg/kg/hour), titrated to hemodynamic response. 1
Clinical Context and Indications
Glucagon is specifically indicated for hypotension when β-blocker therapy complicates treatment, particularly when standard vasopressors fail to restore adequate perfusion due to severe β-adrenergic receptor blockade 2. This represents a Class IIb recommendation (may be helpful) with Level of Evidence C from the 2010 AHA guidelines 1.
The 2023 AHA focused update reinforces this approach, stating it is reasonable to use a bolus of glucagon followed by continuous infusion for bradycardia or hypotension due to β-blocker poisoning (Class 2a, Level C-LD) 3.
Dosing Algorithm
Adults:
- Initial bolus: 3-10 mg IV over 3-5 minutes
- Continuous infusion: 3-5 mg/hour (0.05-0.15 mg/kg followed by 0.05-0.10 mg/kg/hour)
- Titration: Adjust infusion rate to achieve adequate mean arterial pressure and evidence of good perfusion
- Supply planning: May require >100 mg in 24 hours; ensure adequate glucagon availability early 1
Pediatric Patients:
- Initial bolus: 1-5 mg (20-30 mcg/kg, maximum 1 mg) IV over 5 minutes
- Continuous infusion: 5-15 mcg/min, titrated to clinical response 2
Mechanism and Rationale
Glucagon bypasses the β-adrenergic receptor to increase myocardial contractility and heart rate through direct activation of adenylyl cyclase 4. This mechanism remains effective even with complete β-receptor blockade, making it uniquely valuable when catecholamines and other vasopressors fail 5.
Recent evidence from a 2020 randomized trial demonstrates that high-dose glucagon (50 mcg/kg bolus) produces significant hemodynamic effects regardless of β-blockade, increasing heart rate by 13 beats/minute, systolic BP by 15.6 mmHg, and cardiac output by 18% 5.
Critical Management Points
Airway Protection
Protect the airway before glucagon administration in patients with altered mental status. Glucagon commonly causes nausea and vomiting, creating aspiration risk 2. In the 2020 trial, nausea occurred in 80% of participants despite ondansetron pretreatment 5.
Monitoring Requirements
- Continuous hemodynamic monitoring is essential
- Titrate infusion to maintain adequate blood pressure and perfusion
- Monitor for hyperglycemia and hypokalemia (though less concerning than with high-dose insulin therapy)
Infusion vs. Bolus Strategy
The 2020 study suggests that continuous infusion may be preferable to repeated boluses, as it provides comparable hemodynamic effects with apparently longer-lasting benefit 5. This supports the guideline recommendation for bolus followed by continuous infusion rather than repeated boluses alone.
Treatment Hierarchy
Glucagon should be considered after or in conjunction with:
- Volume resuscitation (mandatory first-line)
- Standard vasopressors (epinephrine, dopamine)
- Atropine for bradycardia (though often ineffective in β-blocker toxicity)
The 2023 AHA guidelines now recommend high-dose insulin as first-line therapy (Class 1, Level B-NR) for β-blocker-induced hypotension refractory to vasopressors, with glucagon as an alternative or adjunctive therapy 3.
Important Caveats
- Not indicated for hypotension from other causes (e.g., anaphylaxis without β-blocker use, where epinephrine remains first-line)
- The FDA-approved dosing for severe hypoglycemia (1 mg) is substantially lower than doses needed for β-blocker toxicity 6
- Animal studies suggest concomitant dopamine, isoproterenol, or milrinone may decrease glucagon effectiveness 1
- Cost and limited availability may be practical barriers; plan early for adequate supply 4
Alternative Considerations
If glucagon fails or is unavailable in β-blocker toxicity: